Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

NASDAQ:MDGL - US5588681057 - Common Stock

412.23 USD
-2.45 (-0.59%)
Last: 8/25/2025, 8:00:01 PM
412.23 USD
0 (0%)
After Hours: 8/25/2025, 8:00:01 PM
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While MDGL seems to be doing ok healthwise, there are quite some concerns on its profitability. MDGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MDGL had negative earnings in the past year.
In the past year MDGL has reported a negative cash flow from operations.
In the past 5 years MDGL always reported negative net income.
In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

MDGL has a Return On Assets of -27.76%. This is in the better half of the industry: MDGL outperforms 70.57% of its industry peers.
MDGL's Return On Equity of -40.50% is fine compared to the rest of the industry. MDGL outperforms 71.48% of its industry peers.
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 96.28%, MDGL belongs to the top of the industry, outperforming 95.25% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MDGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDGL has more shares outstanding
Compared to 5 years ago, MDGL has more shares outstanding
Compared to 1 year ago, MDGL has an improved debt to assets ratio.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

MDGL has an Altman-Z score of 15.07. This indicates that MDGL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.07, MDGL belongs to the best of the industry, outperforming 90.13% of the companies in the same industry.
MDGL has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
MDGL's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. MDGL is outperformed by 66.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 15.07
ROIC/WACCN/A
WACC9.7%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 5.11 indicates that MDGL has no problem at all paying its short term obligations.
MDGL has a Current ratio of 5.11. This is comparable to the rest of the industry: MDGL outperforms 55.39% of its industry peers.
MDGL has a Quick Ratio of 4.78. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
MDGL has a Quick ratio of 4.78. This is comparable to the rest of the industry: MDGL outperforms 53.93% of its industry peers.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 4.78
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

MDGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.61%, which is quite impressive.
The Revenue has grown by 3421.98% in the past year. This is a very strong growth!
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%

3.2 Future

MDGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.82% yearly.
Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 86.21% on average per year.
EPS Next Y51.76%
EPS Next 2Y44.56%
EPS Next 3Y42.69%
EPS Next 5Y39.82%
Revenue Next Year401.73%
Revenue Next 2Y181.32%
Revenue Next 3Y127.69%
Revenue Next 5Y86.21%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 -20 40 60 80 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MDGL is valuated quite expensively with a Price/Forward Earnings ratio of 207.53.
MDGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDGL is cheaper than 86.84% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.63. MDGL is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 207.53
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MDGL's earnings are expected to grow with 42.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y42.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (8/25/2025, 8:00:01 PM)

After market: 412.23 0 (0%)

412.23

-2.45 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners98.35%
Inst Owner Change-2.84%
Ins Owners1.03%
Ins Owner Change6.44%
Market Cap9.19B
Analysts82.61
Price Target454.67 (10.3%)
Short Float %19.35%
Short Ratio10.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.12%
Min EPS beat(2)13.46%
Max EPS beat(2)48.79%
EPS beat(4)4
Avg EPS beat(4)32.47%
Min EPS beat(4)13.46%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)13.82%
EPS beat(12)6
Avg EPS beat(12)8.91%
EPS beat(16)9
Avg EPS beat(16)7.2%
Revenue beat(2)2
Avg Revenue beat(2)23.38%
Min Revenue beat(2)18.22%
Max Revenue beat(2)28.53%
Revenue beat(4)4
Avg Revenue beat(4)31.95%
Min Revenue beat(4)2.78%
Max Revenue beat(4)78.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.63%
PT rev (3m)5.64%
EPS NQ rev (1m)36.58%
EPS NQ rev (3m)33.96%
EPS NY rev (1m)21.21%
EPS NY rev (3m)17.44%
Revenue NQ rev (1m)32.17%
Revenue NQ rev (3m)56.81%
Revenue NY rev (1m)27.95%
Revenue NY rev (3m)28.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 207.53
P/S 17.82
P/FCF N/A
P/OCF N/A
P/B 13.2
P/tB 13.29
EV/EBITDA N/A
EPS(TTM)-12.85
EYN/A
EPS(NY)1.99
Fwd EY0.48%
FCF(TTM)-13.84
FCFYN/A
OCF(TTM)-13.79
OCFYN/A
SpS23.13
BVpS31.22
TBVpS31.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.76%
ROE -40.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.28%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.74%
Cap/Sales 0.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.11
Quick Ratio 4.78
Altman-Z 15.07
F-Score3
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.24%
EPS Next Y51.76%
EPS Next 2Y44.56%
EPS Next 3Y42.69%
EPS Next 5Y39.82%
Revenue 1Y (TTM)3421.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1353.76%
Revenue Next Year401.73%
Revenue Next 2Y181.32%
Revenue Next 3Y127.69%
Revenue Next 5Y86.21%
EBIT growth 1Y41.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.21%
EBIT Next 3Y40.7%
EBIT Next 5YN/A
FCF growth 1Y-11.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.99%
OCF growth 3YN/A
OCF growth 5YN/A